Keywords
leprosy
prevention
disabilities
How to Cite
Abstract
Periodical evaluation to prevent physical disabilities is important on follow-up of leprosy patients. This study aimed at comparing the development of the patients’ disabilities examined in two services with different frequencies of evaluation between them. This retrospective cross-historical study observed 30 and 98
patients examined in José Bonifácio, SP and São José do Rio Preto, SP, respectively. At least an initial and final evaluation of the treatment was performed during period of January 1994 to December 1999. To evaluate the development of the disabilities, six indexes were elaborated to compare the initial and final
evaluations. In the first evaluation some kind of disability was present in all multibacillary cases, and 86.7% of paucibacillary in José Bonifácio; 75% of multibacillary and 59% of paucibacillary in São José do Rio Preto. The indexes of nose as well as the strength of upper/inferior limbs, showed that these disabilities were less
frequent, improved or presented no alteration during the treatment in both cities. In São José do Rio Preto, the evolution of disabilities was more satisfactory than in José Bonifácio, according to the general index, eye index and sensitivity of the upper limbs. Regular and adequate evaluation during investigation or monitoring of neural functions can guide professionals to perform actions that can avoid the evolution of impairment caused by the development of neural disorders, mainly in the eyes; the sensitivity of the upper limbs as well as in the general index.
References
2 Roquete AFO, Feitosa DB, Diniz LVG, Madalena M, Lins MD. Avaliação das incapacidades em pacientes hansênicos, atendidos nos serviços públicos de saúde do Distrito Federal com alta em 1995. Rev saúde Dist Fed 1997;8(1):27-40.
3 Secretaria de Estado da Saúde (SP), Guedes JS, Jacintho L, Morais JC, Brasil MTLRF, Nogueira W. Relatório da endemia hansênica Estado de São Paulo. [mimeo]:1997.
4 World Health Organization (WHO). Global leprosy situation in 2003.[online]. Cited 2004 Junho 14. Available from: http://www.who.int/lep/stat 2002/Global 02.htm.
5 Ministério da Saúde (BR). Secretaria de Políticas de Saúde. Sistema de agravos de notificação (SINAN). Prevalência e detecção da hanseníase segundo Unidade Federada-Brasil. [online]. São Paulo 2005. [citado
2005 18 outubro]. Disponível em: http://hanseniase.datasus.gov.br/cgi/deftohtm.exe?hans/hanswsp.def
6 Ministério da Saúde (BR). Secretaria Nacional de Programas Especiais de Saúde. Divisão Nacional de Dermatologia Sanitária. Controle da hanseníase: uma proposta de integração ensino serviço. Rio de Janeiro:
DNDS/NUTES 1989. 124 p.
7 Ministério da Saúde (BR). Secretaria de Políticas da Saúde. Departamento de atenção básica. Área técnica de dermatologia sanitária. Legislação sobre o controle da hanseníase no Brasil. Brasília: Ministério da Saúde 2000. 60 p.
8 Vieth H, Salotti SRA, Passerotti S. Guia de prevenção ocular em hanseníase. Bauru: Centro de Prevenção Oftalmológica; 1994.
9 Merlin L, Willcox K. The impact of multiple drug therapy on leprosy disabilities. Lepr Review 1997;68:350-66.
10 Solomon S, Kurian N, Ramadas P, Rao PS. Incidence of nerve damage in leprosy patients treated with MTD. Int J Lepr 1998;66(4):451-6.
11 Trindade MAB, Lima FD, Almeida RG. Incapacidades físicas na hanseníase no momento do diagnóstico. Hansen int 1987;12(2):9-28.
12 Tiendrebeogo A, Toure I, Zerbo P. A survey of leprosy impairments and disabilities among patients treated by MDT in burkina faso. Int J Lepr 1996;64(1):15-25.
13 Yawalkar SJ. Leprosy for medical practitioner and paramedical workers. 7th ed. Basle: Novartis; 2002.
14 Smith WCS. The epidemiology of disability in leprosy including risk factors. Lepr Review 1992;63 Suppl:23s-30s.
15 Richardus JH, Filay KM, Croft RP, Smith WCS. Nerve function impairment in leprosy at diagnosis and at completion of MDT: a retrospective cohort study of 786 patients in Bangladesh. Lepr Review 1996;67:297-305.
16 Soubhia RMC. Plano de eliminação da hanseníase na região de São José do Rio Preto. [Apostilado]. São José do Rio Preto: DIR XXII; 1996.
17 Centro de Vigilância Epidemiológica Prof. Alexandre Vranjac. Programa de Controle da Hanseníase. [mimeo]. São José do Rio Preto: DIR XXII; 1998.
18 Helene LMF, Leão VM, Minakawa MM. Perfis epidemiológicos e a avaliações de incapacidades físicas de hansenianos de uma UBS de São Paulo. Hansen int 2001;26(1):5-13.
19 Ferreira J. Validade do grau de incapacidades como indicadores de diagnóstico tardio da hanseníase. Hansen int Special 1998;79-84.
20 Sharma P, Kar HK, Beena KR, Kaur H, Narayan R. Disabilities in multibacillary leprosy patients before, during and after multidrug therapy. Indian J Lepr 1996;68(2):127-36.
21 Smith WCS, Zhang G, Zheng T, Watson JM, Lehman LF, Lever P. Prevention of impairment in leprosy: results from a collaborative project in China. Int J Lepr 1995;63:507-17.
22 Cristofolini L, Ogusku EF. Proposta para avaliação e cuidados nasais na hanseníase. Salusvita 1988;7(1):129-36.
23 Virmond M, Vieth H. Prevenção de incapacidades na hanseníase: uma análise crítica. Medicina 1997;30:358-63.
24 Garbino JA. Manejo clínico das diferentes formas de comprometimento da neuropatia hanseniana. Hansen int Special 1998;93-99.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Downloads
